レジェネロン製薬は投資家の関心が上がり 4Qの業績が好調で 株価が上昇した. Regeneron Pharmaceuticals saw increased investor interest and strong Q4 earnings, boosting its stock.

レジェネロン製薬は第4四半期に3.8%の機関保有額を増加させ,様々な投資家が彼らの株価を調整した. Regeneron Pharmaceuticals saw a 3.8% rise in institutional holdings in the fourth quarter, with various investors adjusting their stakes. 株式会社Q4収益率が12.07でトップは8.6ドルと予想され,当該株式総額の4分の1の配当額は8分の8と発表した. The company's Q4 earnings per share of $12.07 topped forecasts by $0.86, and it announced a quarterly dividend of $0.88 per share. 分析家のレジェネロンに対する評価は"適度な購入"と973.13ドルの目標価格との間で異なる. Analysts' ratings on Regeneron vary, with a consensus "Moderate Buy" and a target price of $973.13. 会社の市場キャップは,79.09億円です. The company's market cap is $79.09 billion.